Table 1 Association between SNCG expression and clinicopathologic characteristics of patients with prostate cancer
| Â | SNCG | NO. samples | P | ||||
|---|---|---|---|---|---|---|---|
| Â | - | + | ++ | +++ | Â | Â | |
Prostatitis tissues | 10 | 0 | 0 | 0 | 10 | <0.001 | |
BPH tissues | 8 | 0 | 2 | 0 | 10 | <0.001 | |
Prostate cancer tissues (androgen-independent) | 5 | 0 | 0 | 0 | 5 | <0.001 | |
Prostate cancer tissues (androgen-dependent) | 48 | 24 | 31 | 19 | 122 | Â | |
PSA | <10 | 22(57.9%) | 9(23.7%) | 6(15.8%) | 1(3.6%) | 38 | 0.004 |
|  | ≥10 | 26(31.0%) | 15(17.9%) | 25(29.8%) | 18(21.3%) | 84 |  |
Gleason score | ≤6 | 19(59.3%) | 6(18.8%) | 5(15.6%) | 2(6.3%) | 32 | 0.037 |
|  | ≥7 | 29(32.2%) | 18(20.0%) | 26(28.9%) | 17(18.9%) | 90 |  |
Clinical stage | ≤T2a | 13(52.0%) | 7(28.0%) | 3(12.0%) | 2(8.0%) | 25 | 0.042 |
|  | ≥T2b | 35(36.1%) | 17(17.5%) | 28(28.9%) | 17(17.5%) | 97 |  |
Lymph node invasion | Negative | 46(42.2%) | 24(22.0%) | 28(25.7%) | 11(10.1%) | 109 | <0.001 |
| Â | positive | 2(15.4%) | 0 | 3(23.1%) | 8(61.5%) | 13 | Â |
AR | - | 19(44.2%) | 8(18.6%) | 10(23.3%) | 6(13.9%) | 43 | 0.881 |
| Â | + | 29(36.7%) | 16(20.3%) | 21(26.6%) | 13(16.4%) | 79 | Â |